Carroll Investors Inc Has $1.67 Million Holdings in Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX)

Carroll Investors Inc boosted its stake in shares of Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX - Free Report) by 51.8% during the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 246,985 shares of the company's stock after acquiring an additional 84,245 shares during the quarter. Recursion Pharmaceuticals makes up approximately 0.9% of Carroll Investors Inc's holdings, making the stock its 15th biggest holding. Carroll Investors Inc owned about 0.06% of Recursion Pharmaceuticals worth $1,670,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also modified their holdings of the company. Accel Wealth Management bought a new position in shares of Recursion Pharmaceuticals in the 4th quarter worth $310,000. Avanza Fonder AB bought a new position in Recursion Pharmaceuticals during the fourth quarter worth about $580,000. State Street Corp grew its position in shares of Recursion Pharmaceuticals by 47.1% during the 3rd quarter. State Street Corp now owns 12,870,272 shares of the company's stock worth $84,815,000 after buying an additional 4,120,685 shares during the period. Institute for Wealth Management LLC. bought a new stake in shares of Recursion Pharmaceuticals in the 4th quarter valued at about $3,928,000. Finally, Geode Capital Management LLC increased its stake in Recursion Pharmaceuticals by 13.7% in the third quarter. Geode Capital Management LLC now owns 5,431,911 shares of the company's stock valued at $35,803,000 after purchasing an additional 656,003 shares in the last quarter. Institutional investors and hedge funds own 89.06% of the company's stock.

Recursion Pharmaceuticals Stock Performance

Recursion Pharmaceuticals stock traded up $0.18 during trading hours on Friday, hitting $5.50. The company had a trading volume of 12,710,040 shares, compared to its average volume of 12,004,554. The firm has a market cap of $2.21 billion, a PE ratio of -3.59 and a beta of 1.00. The firm has a 50-day moving average of $6.66 and a 200 day moving average of $6.80. The company has a debt-to-equity ratio of 0.04, a current ratio of 4.35 and a quick ratio of 4.35. Recursion Pharmaceuticals, Inc. has a one year low of $3.79 and a one year high of $12.36.

Recursion Pharmaceuticals (NASDAQ:RXRX - Get Free Report) last posted its earnings results on Friday, February 28th. The company reported ($0.53) earnings per share for the quarter, missing analysts' consensus estimates of ($0.36) by ($0.17). Recursion Pharmaceuticals had a negative return on equity of 76.56% and a negative net margin of 579.52%. The firm had revenue of $4.60 million for the quarter, compared to analyst estimates of $19.04 million. During the same period in the prior year, the business posted ($0.42) EPS. The firm's quarterly revenue was down 57.8% compared to the same quarter last year. On average, sell-side analysts expect that Recursion Pharmaceuticals, Inc. will post -1.57 earnings per share for the current year.

Wall Street Analysts Forecast Growth

A number of research firms recently issued reports on RXRX. Morgan Stanley lowered their target price on Recursion Pharmaceuticals from $10.00 to $8.00 and set an "equal weight" rating for the company in a research note on Thursday, April 10th. Leerink Partners lowered their price objective on shares of Recursion Pharmaceuticals from $7.00 to $6.00 and set a "market perform" rating for the company in a research report on Friday, February 28th. Cowen reaffirmed a "hold" rating on shares of Recursion Pharmaceuticals in a research report on Friday, February 28th. Needham & Company LLC reiterated a "buy" rating and set a $11.00 target price on shares of Recursion Pharmaceuticals in a report on Tuesday, April 8th. Finally, KeyCorp cut their price target on Recursion Pharmaceuticals from $12.00 to $10.00 and set an "overweight" rating on the stock in a report on Wednesday, January 8th. Four investment analysts have rated the stock with a hold rating and two have issued a buy rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of "Hold" and an average target price of $8.20.

About Recursion Pharmaceuticals

Recursion Pharmaceuticals, Inc operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers.